



Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-298-999	APPLICATION NO. 10/784,012
APPLICANT Srivastava, P.	
FILING DATE February 20, 2004	ART UNIT 1643

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	09/625,137	7/25/2000	Srivastava	
	A02	09/668,724	9/22/2000	Srivastava	
	A03	09/693,643	10/20/2000	Srivastava	
	A04	20020028207	6/4/2001	Srivastava	
	A05	20020037290	3/28/2002	Armen	
	A06	20020172682	11/21/2002	Srivastava	
	A07	20020192230	12/19/2002	Srivastava	
	A08	20030129196	7/10/2003	Srivastava et al.	
	A09	20030129206	7/10/2003	Ulbrich et al.	
	A10	20030211971	11/13/2003	Srivastava	
	A11	20040022796	2/5/2004	Srivastava	
	A12	4,690,915	9/1/1987	Rosenberg	
	A13	5,188,964	2/23/1993	McGuire et al.	
	A14	5,232,833	8/3/1993	Sanders et al.	
	A15	5,348,945	9/20/1994	Berberian et al.	
	A16	5,580,859	12/3/1996	Felgner et al.	
	A17	5,652,115	7/29/1997	Marks et al.	
	A18	5,736,146	4/7/1998	Cohen	
	A19	5,747,332	5/5/1998	Wallen et al	
	A20	5,750,119	5/12/1998	Srivastava	
	A21	5,830,464	11/3/1998	Srivastava	
	A22	5,837,251	11/17/1998	Srivastava	
	A23	5,869,058	2/9/1999	Cohen	
	A24	5,891,653	4/6/1999	Attfield	
	A25	5,935,576	8/10/1999	Srivastava	
	A26	5,948,646	7/9/1999	Srivastava et al.	
	A27	5,961,979	10/5/1999	Srivastava	
	A28	5,985,270	11/16/1999	Srivastava	
	A29	5,997,873	12/7/1999	Srivastava et al.	
	A30	6,017,540	1/25/2000	Srivastava	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-298-999

APPLICATION NO.

10/784,012

APPLICANT

Srivastava, P.

FILING DATE

February 20, 2004

ART UNIT

1643

U.S. PATENT DOCUMENTS

	A31	6,030,618	2/29/2000	Srivastava	
	A32	6,048,530	4/11/2000	Srivastava	
	A33	6,136,315	10/24/2000	Srivastava	
	A34	6,162,436	12/19/2000	Srivastava	
	A35	6,168,793	1/2/2001	Srivastava et al.	
	A36	6,312,711	11/6/2001	Duchateau et al.	
	A37	6,338,945	1/15/2002	Nicolette, Charles A.	
	A38	6,399,070	6/4/2002	Srivastava et al.	
	A39	6,403,092	6/11/2002	Pizzo et al.	
	A40	6,433,141	8/13/2002	Wallen et al.	
	A41	6,689,363	2/10/2004	Sette et al.	
	A42	6,709,672	3/23/2004	Henot et al.	
	A43	6,713,608	3/30/2004	Wallen et al.	
	A44	6,730,302	5/4/2004	Fujihara et al.	
	A45	6,797,480	9/28/2004	Srivastava	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	DE 19602985	1/27/1996	Max Delbrueck Centrum (DE)		
	B02	GB 2251186	7/1/1992	Gatz Randall and Bromley		
	B03	WO 0010597	3/2/2000	Immunobiology Ltd (GB)		
	B04	WO 0054801	9/21/2000	Entremed Inc (US)		
	B05	WO 04075636	9/10/2004	Univ Connecticut Health Center (US)		
	B06	WO 0191787	6/12/2001	Univ Connecticut Health Center (US)		
	B07	WO 0192474	12/16/2001	Univ of Connecticut Health Center (US)		
	B08	WO 0215930	2/28/2002	Duke Univ (US)		
	B09	WO 0230434	4/18/2002	Univ Connecticut Health Center (US)		
	B10	WO 0232923	4/25/2002	Univ Connecticut Health Center (US)		
	B11	WO 0234205	5/2/2002	Univ Connecticut Health Center (US)		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p><i>Substitute for Form 1449A</i></p> <p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p>	ATTY. DOCKET NO. 8449-298-999	APPLICATION NO. 10/784,012
	APPLICANT Srivastava, P.	
	FILING DATE February 20, 2004	ART UNIT 1643

	B12	WO 03015712	2/27/2003	Univ Connecticut Health Center (US)		
	B13	WO 03090686	11/6/2003	Univ Connecticut Health Center (US)		
	B14	WO 03092624	11/13/2003	Univ Connecticut Health Center (US)		
	B15	WO 8912455	12/28/1989	Whitehead Biomedical Inst (US); Medical Res Council (GB)		
	B16	WO 9002564	3/22/1990	Codon (US)		
	B17	WO 9115572	10/17/1991	Wellcome Found (GB)		
	B18	WO 9201717	2/6/1992	Burnie James P (GB)		
	B19	WO 9208484	5/29/1992	Univ London (GB)		
	B20	WO 9208488	5/29/1992	Univ London (GB)		
	B21	WO 9314118	7/22/1993	Medical Res Council (GB)		
	B22	WO 9317712	9/16/1993	Sclavo Biocine Spa (IT)		
	B23	WO 9318146	9/16/1993	Inst Nat Sante Rech Med (FR)		
	B24	WO 9318147	9/16/1993	Ist Naz Stud Cura Dei Tumori (IT)		
	B25	WO 9318150	9/16/1993	Sclavo Biocine Spa (IT)		
	B26	WO 9321529	10/28/1993	Duke Univ (US); Abbott Lab (US)		
	B27	WO 9324136	12/9/1993	Terman David S (US); Stone Jay L (US)		
	B28	WO 9403208	2/17/1994	Yeda Res. & Dev. (IL) et al.		
	B29	WO 9404676	3/3/1994	Univ Manchester (GB) et al.		
	B30	WO 9411513	5/26/1994	Medical Res Council (GB) et al.		
	B31	WO 9414976	7/7/1994	Duke Univ (US) et al		
	B32	WO 9429459	12/22/1994	Whitehead Biomedical Inst (US)		
	B33	WO 9524923	9/21/1995	Mt. Sinai School Medicine (US) et al.		
	B34	WO 9610411	4/11/1996	Mt. Sinai School Medicine (US)		
	B35	WO 9706685	2/27/1997	Sloan Kettering Inst Cancer (US) et al.		
	B36	WO 9706821	2/27/1997	Sloan Kettering Inst Cancer (US) et al.		
	B37	WO 9706828	2/27/1997	Sloan Kettering Inst Cancer (US) et al		
	B38	WO 9710000	3/20/1997	Fordham Univ (US)		
	B39	WO 9710001	3/20/1997	Fordham Univ (US)		
	B40	WO 9710002	3/20/1997	Fordham Univ (US)		
	B41	WO 9726910	7/31/1997	Max Delbrueck Centrum (DE); Wellcome Trust Limited As Trustee (GB); Merck & Co Inc (US);		
	B42	WO 9846743	10/22/1998			
	B43	WO 9929834	6/17/1999	Fordham Univ (US)		
	B44	WO 04074454	4/2/2004	Univ Connecticut Health Center (US)		

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C01	ALDOVINI <i>et al.</i> , 1992, "The New Vaccines", <i>Tech. Rev.</i> pp. 24-31	
C02	AMATO <i>et al.</i> , 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" <i>ASCO Meeting Genitourinary Cancer: Abs # 1278</i>	
C03	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," <i>Infect. Immun.</i> 62(6):2536-44	
C04	ANTHONY <i>et al.</i> , 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," <i>Vaccine</i> 17(4):373-83	
C05	ARNOLD <i>et al.</i> , 1995, "Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96", <i>J Exp Med.</i> Sep 1;182(3):885-9	
C06	ARNOLD-SCHILD <i>et al.</i> , 1999, "Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells", <i>J. Immunol.</i> 162: 3757-3760	
C07	ASEA <i>et al.</i> , 2000, "HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine," <i>Nat. Med.</i> 6:435-442	
C08	BANCHEREAU <i>et al.</i> , 1998, "Dendritic cells and the control of immunity," <i>Nat.</i> 392:245-252	
C09	BARRIOS <i>et al.</i> , 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming," <i>Eur. J. Immunol.</i> 22(6):1365-72	
C10	BARRIOS <i>et al.</i> , 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and DNA K proteins requires cross-linking with antigen," <i>Clin. Exp. Immunol.</i> 98(2):229-233	
C11	BARRIOS <i>et al.</i> , 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." <i>Clin Exp Immunol.</i> 98(2):224-8	
C12	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors", <i>J. Natl. Cancer Inst.</i> 49:493-504	
C13	BASOMBRIO, 1970 "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
C14	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" <i>J. Exp. Med.</i> 189:797-802	
C15	BASU <i>et al.</i> , 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," <i>Int. Immunol.</i> 12(11):1539-46	
C16	BEVAN, 1995, "Antigen presentation to cytotoxic T lymphocytes in vivo", <i>J. Exp. Med.</i> 192: 639-41	
C17	BEVERLY, 1988, "Tumour Immunology", In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	
C18	BHATTACHARJEE <i>et al.</i> , 1999, "Incorporation of non-proteolytic proteins by murine alpha-2 macroglobulin", <i>Biochimica et Biophysica Acta</i> 1432:49-56	
C19	BINDER <i>et al.</i> , 2001, "Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91." <i>J Immunol.</i> 166(8):4968-72	
C20	BINDER <i>et al.</i> , 2002 "Naturally formed or artificially reconstituted non-covalent alpha2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity." <i>Cancer Immun.</i> Dec 18;2:16-24	
C21	BINDER <i>et al.</i> , 1998, "Receptor-dependent and receptor-independent representation of heat-shock protein-chaperoned peptides." <i>Cell Stress & Chaperones</i> 3 (Supp.1): 2.	
C22	BIRKENMEIER G., 2001, "Targeting the Proteinase Inhibitor and Immune Modulatory Function of Human alpha2-Macroglobulin." <i>Mod. Asp. Immunobiol.</i> 2(1):32-36	
C23	BLACHERE and SRIVASTAVA, 1993, "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", <i>J. Cellular Biochem. Keystone Symposia</i> , 17D: pp. 124, Abstract NZ 502	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C24	BLACHERE <i>et al.</i> , 1993, "Heat Shock Protein Vaccines Against Cancer," <i>Journal of Immunotherapy</i> 14:352-356
	C25	BLACHERE <i>et al.</i> , 1997, "Heat shock protein-peptide complexes reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity," <i>J. Exp. Med.</i> 186(8):1315-22
	C26	BLANDER <i>et al.</i> , 1993, "Major cytoplasmic membrane protein of Legionella pneumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," <i>J. Clin. Invest.</i> 91(2):717-23
	C27	BRELOER <i>et al.</i> , 1999, "In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," <i>J. Immunol.</i> 162:3141-3147
	C28	BUMOL <i>et al.</i> , 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody", <i>Hybridoma</i> 7:407-415
	C29	CARSWELL <i>et al.</i> , 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice", <i>J. Natl. Cancer Inst.</i> 44:1281-1288
	C30	CASSEL <i>et al.</i> , 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate", <i>Cancer</i> , 52:856-860
	C31	CASSEL <i>et al.</i> , 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," <i>Cancer</i> 40:672-679
	C32	CASTELLINO <i>et al.</i> , 2000, "Receptor-mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways", <i>J. Exp. Med.</i> 191:1957-64
	C33	CHEN <i>et al.</i> , 1999, "Human 60-kDa heat-shock protein: a danger signal to the innate immune system," <i>J. Immunol.</i> 162:3212-3219
	C34	CHU and PIZZO, 1993, "Receptor-Mediated Antigen Delivery into Macrophages," <i>J. Immunol.</i> 150(1):48-58
	C35	CHU and PIZZO, 1994, "α ₂ -Macroglobulin, Complement, and Biologic Defense: Antigens, Growth Factors, Microbial Proteases, and Receptor, Ligation," <i>Lab. Invest.</i> 71:792-812
	C36	CHU <i>et al.</i> , 1994, "Adjuvant-Free In Vivo Targeting Antigen Delivery by α-Macroglobulin Enhances Antibody Formation," <i>J. Immunol.</i> 152(4):1538-1545
	C37	CHU <i>et al.</i> , 1994, α ₂ -Macroglobulin: A Sensor for Proteolysis," <i>Ann. N.Y. Acad. Sci.</i> 737:291-307
	C38	CIUPITU <i>et al.</i> , 1998, "Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes", <i>J Exp Med.</i> 187(5):685-91
	C39	CLARKE <i>et al.</i> 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" <i>Mol. and Cell. Biol.</i> Vol. 8 (3) 1206-1215
	C40	COUTINHO <i>et al.</i> , 1998, "Alpha-2-macroglobulin receptor is differently expressed in peritoneal macrophages from C3H and C57/B16 mice and up-regulated during Trypanosoma cruzi infection", <i>Tissue and Cell</i> 30: 407-15
	C41	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," <i>Science</i> 260:1902-4
	C42	DASH, <i>et al.</i> , 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor," <i>J. Biol. Chem.</i> 277:17978-17986
	C43	DAVIDOFF <i>et al.</i> , 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers" <i>Proc Natl Acad Sci U S A.</i> ;89(8):3439-42
	C44	DAY <i>et al.</i> , 1997, "Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells", <i>Proc Natl Acad Sci. USA</i> 94: 8064-8069
	C45	DEL GIUDICE <i>et al.</i> , 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", <i>Experientia</i> 50:50(11-12):1061-6
	C46	DENNIS <i>et al.</i> , 1989, "Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor", <i>J Biol Chem.</i> 264(13):7210-6
	C47	DEUTSCHER <i>et al.</i> , 1992 "Guide to protein purification" <i>Meth. Enzymol.</i> , 182:779-780
	C48	DUBOIS <i>et al.</i> , 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," <i>Cancer Res.</i> 40:4204-4208

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C49	DUBOIS, <i>et al.</i> , 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas," <i>Proc. Natl. Acad. Sci USA</i> , 79:7669-7673	
C50	ESTIN <i>et al.</i> , 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," <i>J. Natl. Cancer Inst.</i> 81:445-448	
C51	FALK <i>et al.</i> , 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", <i>Nature</i> 348:248-251	
C52	FALK <i>et al.</i> , 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast" <i>J. Exp. Med.</i> 174:425-434	
C53	FALK <i>et al.</i> , 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", <i>Nature</i> 351:290-296	
C54	FALK <i>et al.</i> , 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", <i>Eur. J. Immunol.</i> 22:1323-1326	
C55	FELDWEIG and SRIVASTAVA, 1993, "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", <i>Journal of Cellular Biochemistry Supplement</i> 0 (17 PART D): p 108	
C56	FENG <i>et al.</i> , 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," <i>AACR 93rd Annual Meeting</i> , Vol. 43, April 6-10, Abstract #2214	
C57	FERRERO <i>et al.</i> , 1995, "The GroES homolog of <i>Helicobacter pylori</i> confers protective immunity against mucosal infection in mice." <i>Proc Natl Acad Sci USA</i> 92(14):6499-503	
C58	FLYNN <i>et al.</i> , 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly", <i>Science</i> 245:385-390	
C59	FLYNN <i>et al.</i> , 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", <i>Nature</i> 353:726-730	
C60	FORRESTER <i>et al.</i> , 1983, "Effect of modified alpha 2 macroglobulin on leucocyte locomotion and chemotaxis", <i>Immunology</i> 50(2):251-9	
C61	GALLUCCI <i>et al.</i> , 1999, "Natural adjuvants: endogenous activators of dendritic cells," <i>Nat. Med.</i> 5:1249-55	
C62	GELBER <i>et al.</i> , 1992, "Vaccination of mice with a soluble protein fraction of <i>Mycobacterium leprae</i> provides consistent and long-term protection against <i>M. leprae</i> infection," <i>Infect Immun.</i> 60(5):1840-4	
C63	GELBER <i>et al.</i> , 1994, "Vaccination with pure <i>Mycobacterium leprae</i> proteins inhibits <i>M. leprae</i> multiplication in mouse footpads," <i>Infect Immun.</i> 62(10):4250-5	
C64	GETHING <i>et al.</i> , 1992, "Protein folding in the cell," <i>Nature</i> 355:33-45	
C65	GOMEZ <i>et al.</i> , 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of <i>Histoplasma capsulatum</i> yeast cells." <i>Infect Immun.</i> 59(12):4459-64	
C66	GOMEZ <i>et al.</i> , 1992, "An 80-kilodalton antigen from <i>Histoplasma capsulatum</i> that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," <i>Infect Immun.</i> 60(7):2565-71	
C67	GOMEZ <i>et al.</i> , 1995, "Vaccination with recombinant heat shock protein 60 from <i>Histoplasma capsulatum</i> protects mice against pulmonary histoplasmosis." <i>Infect Immun.</i> 63(7):2587-95	
C68	GRAHAM, <i>et al.</i> , 1955, "Antibodies Elicited by Cancer in Patients," <i>Cancer</i> 8:409-416	
C69	GRANER <i>et al.</i> 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" <i>Clin. Can. Res.</i> 6:909	
C70	GRANER <i>et al.</i> , 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" <i>Cancer Immunol. Immunother.</i> 49:476	
C71	GRANER <i>et al.</i> , 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," <i>Cancer Immunol. Immunother.</i> 52(4):226-234	
C72	GRIFFEN, Jr., <i>et al.</i> 1972, "Colon Carcinoma and Immunologic Phenomena," <i>Surgical Clinics of North America</i> , Vol. 52:839-846	
C73	GRON and PIZZO, 1998, "Non proteolytic Incorporation of Protein Ligands into Human α_2 macroglobulin: Implications for the binding mechanism of α_2 -macroglobulin", <i>Biochem.</i> 37:6009-6014	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C74	GROBMANN <i>et al.</i> , 1997 "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines", <i>Anticancer Res.</i> 17: 3117-3120	
C75	HALEVY <i>et al.</i> 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities", <i>Science</i> Vol. 250 113-116	
C76	HALL <i>et al.</i> , 1981, "Proteolytic Cleavage Sites on α_2 -Macroglobulin Resulting in Proteinase Binding are Different for Trypsin and Staphylococcus Aureus V-8 Proteinase," <i>Biochem. Biophys. Res. Commun.</i> 100(1):8-16	
C77	HEISKALA <i>et al.</i> , 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity", <i>Scand. J. Immunol.</i> 28:19-27	
C78	HENTTU and VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes", <i>Biochem. Biophys. Res. Comm.</i> 160:903-910	
C79	HINDS <i>et al.</i> , 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" <i>Mol. and Cell. Biol.</i> Vol.7 (8) 2863-2869	
C80	HINDS <i>et al.</i> , 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" <i>Cell Growth and Differentiation</i> Vol. 1 571-580	
C81	HOLLINSHEAD, 1988, "Immunotherapy," in: <i>Cancer: The Outlaw Cell</i> , LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)	
C82	HOLTET <i>et al.</i> , 1994, "Recombinant α_2 M Receptor binding domain binds to the α_2 M receptor with high affinity", <i>Ann NY Acad Sci.</i> 737:480-2	
C83	HOLTET <i>et al.</i> , 1994, "Receptor-binding domain of human α_2 -macroglobulin Expression, folding and biochemical characterization of a high-affinity recombinant derivative," <i>FEBS Lett.</i> 344:242-6	
C84	HORWITZ <i>et al.</i> , 1995, "Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis." <i>Proc Natl Acad Sci U S A.</i> 92(5):1530-4	
C85	HUANG <i>et al.</i> , 1984, "Specific covalent binding of platelet-derived growth factor to human plasma alpha 2-macroglobulin." <i>Proc Natl Acad Sci U S A.</i> 81(2):342-6	
C86	HUANG <i>et al.</i> , 1996, "The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product", <i>Proc Natl Acad Sci U S A.</i> 93(18):9730-5	
C87	HUBBARD <i>et al.</i> , 1992, "Immunization of mice with mycobacterial culture filtrate proteins," <i>Clin. Exp. Immunol.</i> 87(1):94-8	
C88	HUGHES <i>et al.</i> , 1970, "A Study In Clinical Cancer Immunotherapy", <i>Cancer</i> , 26:269-278	
C89	HUMPHREY <i>et al.</i> , 1984, "Adjuvant immunotherapy for melanoma," <i>J. Surg. Oncol.</i> 25:303-305	
C90	HUNT <i>et al.</i> , 1990, "Characterization and sequence of a mouse hsp70 gene and its expression in mouse cell lines", <i>Gene</i> 87(2):199-204	
C91	ISHII <i>et al.</i> , 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", <i>J Immunol.</i> 162(3):1303-9	
C92	ISRAELI <i>et al.</i> , 1993, "Molecular Cloning Of A Complementary DNA Encoding A Prostate-Specific Membrane Antigen", <i>Cancer Res.</i> 53:227-230	
C93	JAKOB <i>et al.</i> , 1993, "Small Heat Shock Proteins Are Molecular Chaperones", <i>J. Biol. Chem.</i> 268:1517-1520	
C94	JANETZKI <i>et al.</i> , 2000, "Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study" <i>Int. J. of Cancer</i> 88:232-238	
C95	JARDETZKY <i>et al.</i> , 1991, "Identification of Self Peptides Bound to Purified HLA-B27", <i>Nature</i> 353:326-329	
C96	JINDAL <i>et al.</i> , 1989, "Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen." <i>Mol Cell Biol.</i> 9(5):2279-83	
C97	JOCHAM <i>et al.</i> , 2004, "Adjuvant Autologous Renal Tumour Cell Vaccine and Risk of Tumour Progression in Patients with Renal-Cell Carcinoma After Radical Nephrectomy: Phase III, Randomised Controlled Trial," <i>The Lancet</i> , Vol 363:594-599	

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT	
	Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C98	KATSANIS <i>et al.</i> , 2000, "Augmentation of Tumor Lysate Immunogenicity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" <i>Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer</i> , abstract 431	
C99	KOJIMA <i>et al.</i> , 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," <i>AACR 93rd Annual Meeting</i> , Vol. 43, Abstract #5516	
C100	KOL <i>et al.</i> , 2000, "Cutting edge: heat shock protein (HSP)60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells", <i>J Immunol.</i> 164(1):13-17	
C101	KRIPKE, 1974 "Antigenicity Of Murine Skin Tumors Induced By Ultraviolet Light", <i>J. Natl. Cancer Inst.</i> 53:1333-1336	
C102	KRISTENSEN <i>et al.</i> , 1990, "Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor", <i>FEBS Lett.</i> 276(1-2):151-5	
C103	LAKEY <i>et al.</i> , 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", <i>Proc. Natl. Acad. Sci. USA</i> 84:1659-1663	
C104	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", <i>Science</i> 260:937-944	
C105	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", <i>Cell</i> 67:265-274	
C106	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", <i>EMBO J.</i> 12(8):3143-3151	
C107	LINDQUIST <i>et al.</i> , 1988, "The Heat-Shock Proteins," <i>Ann. Rev. Genetics</i> 22:631-77	
C108	LIVINGSTON <i>et al.</i> , 1985, "Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells," <i>Cancer</i> , 55:713-720 (1985)	
C109	LUESCHER <i>et al.</i> , 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", <i>Nature</i> 351:72-77	
C110	LUKACS <i>et al.</i> , 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", <i>J. Exp. Med.</i> 178:343-348	
C111	LUSSOW <i>et al.</i> , 1991, "Mycobacterial heat-shock proteins as carrier molecules", <i>Eur J Immunol.</i> 21(10):2297-302	
C112	MADDEN <i>et al.</i> , 1991, "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended Conformation", <i>Nature</i> 353:321-325	
C113	MAKI, 1991 "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", <i>Ph.D. thesis, Cornell University</i>	
C114	MAKI <i>et al.</i> , 1990, "Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins", <i>Proc Natl Acad Sci U S A.</i> 87(15):5658-63	
C115	MARTIN <i>et al.</i> , 1986, "Role of Murine Tumor Models in Cancer Treatment Research", <i>Cancer Research</i> 46:2189-2192	
C116	MATSUTAKE <i>et al.</i> , 2001, "The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein," <i>Proc. Natl. Acad. Sci. USA</i> 98(7):3992-3997	
C117	MELCHER <i>et al.</i> , 1998, "Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression", <i>Nat. Med.</i> 5:581-7	
C118	MELIEF <i>et al.</i> , 1992, "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General", <i>Career Surveys</i> 13:81-99	
C119	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, <i>American Society for Microbiology</i> pp. 1-13	
C120	MENORET and CHANDAWARKAR, 1998, "Heat-shock protein-based anticancer immunotherapy: an idea whose time has come" <i>Semin. in Oncology</i> 25:654	
C121	MENORET <i>et al.</i> , 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas," <i>J. Immunol.</i> 155:740-7	
C122	MENORET <i>et al.</i> , 1999, "Association of peptides with heat shock protein gp96 occurs in vivo and not after cell lysis", <i>Biochem Biophys Res Commun.</i> 262(3):813-8	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C123	MILLIPORE PUBLICATIONS: "Ultrafiltration Disc Membranes for Stirred Cells and Micropartition System (Mps)," http://www.millipore.com/publications.nsf/docs/tn1000enus accessed on September 21, 2004	
C124	MISRA <i>et al.</i> , 1993, "Receptor-recognized alpha 2-macroglobulin-methylamine elevates intracellular calcium, inositol phosphates and cyclic AMP in murine peritoneal macrophages", <i>Biochem J.</i> 290 (Pt 3):885-91	
C125	MITSUDA <i>et al.</i> , 1993, "A receptor-mediated antigen delivery and incorporation system. Administration of alpha 2-macroglobulin-cytochrome c conjugate induced high concentrations of antibodies against cytochrome c in mice." <i>Biochem Biophys Res Commun.</i> 191(3):1326-31	
C126	MIZZEN <i>et al.</i> , 1998, "Immune responses to stress proteins: applications to infectious disease and cancer," <i>Biotherapy</i> 10:173-185	
C127	MOESTRUP <i>et al.</i> , 1992, "Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues", <i>Cell Tissue Res.</i> 269(3):375-82	
C128	MOESTRUP <i>et al.</i> , 1993, "α ₂ -macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the α ₂ -macroglobulin receptor containing a cluster of eight complement type repeats", <i>J. Biol. Chem.</i> 268: 13691-13696	
C129	MULÉ <i>et al.</i> , 1984, "Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2", <i>Science</i> 225:1487-1489	
C130	MUNRO <i>et al.</i> , 1986, "An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein", <i>Cell</i> 46(2):291-300	
C131	MURRAY <i>et al.</i> , 1977 "Viral Oncolysate in the Management of Malignant Melanoma II, Clinical Studies", <i>Cancer</i> 40:680-686	
C132	NAIR <i>et al.</i> , 1977 "Antigen-Presenting Cells Pulsed With Unfractionated Tumor-Derived Peptides Are Potent Tumor Vaccines", <i>Eur. J. Immunol.</i> 27:589-597	
C133	NAIR <i>et al.</i> , 1999, "Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides" <i>J. Immunol.</i> 162:6426	
C134	NATALI <i>et al.</i> , 1987 "Immunohistochemical Detection Of Antigen In Human Primary And Metastatic Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance", <i>Cancer</i> , 59:55-63	
C135	NICCHITTA <i>et al.</i> , 1998, "Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96", <i>Curr Opin Immunol.</i> 10(1):103-9	
C136	NIELAND <i>et al.</i> , 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94", <i>Proc. Natl. Acad. Sci. USA</i> 93:6135-6139	
C137	NIELSEN <i>et al.</i> , 1996, "Identification of Residues in α ₂ -Macroglobulins Important for Binding to the α ₂ -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein," <i>J. Biol. Chem.</i> 271:12909-12912	
C138	NOGUCHI <i>et al.</i> , 1994, "A Mouse p53 Product Recognized by CD4 ⁺ and CD8 ⁺ T Cells," <i>Proc. Natl. Acad. Sci USA</i> 91:3171-3175	
C139	NORBURY <i>et al.</i> , 1997, "Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells", <i>Eur J Immunol.</i> 27(1):280-8	
C140	NORRBY, 1985, "Summary," in: <i>Vaccines 85</i> , Lerner <i>et al.</i> , eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY pp. 387-394	
C141	NYKJAER <i>et al.</i> , 1992, "Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes", <i>J Biol Chem.</i> 267(21):14543-6	
C142	O'CONNOR-MCCOURT <i>et al.</i> , 1987, "Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin", <i>J Biol Chem.</i> 262(29):14090-9	
C143	OETTGEN and OLD, 1991 "The History Of Cancer Immunotherapy", In: <i>Introduction To The Biologic Therapy Of Cancer</i> ", Devitta <i>et al.</i> , Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)	
C144	OHASHI <i>et al.</i> , 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. <i>J. Immunol.</i> 164:558-561	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT	
	Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C145	OLD <i>et al.</i> , 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced Tumors", <i>Ann. N.Y. Acad. Sci.</i> <u>101</u> :80-106	
C146	ORIT PINHASI-KIMHI <i>et al.</i> 1986, "Specific interaction between the p53 cellular tumor antigen and major heat shock proteins", <i>Nature</i> Vol 320 (13) 182-184	
C147	ORTH <i>et al.</i> , 1992, "Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor", <i>Proc Natl Acad Sci U S A.</i> 89(16):7422-6	
C148	OSADA <i>et al.</i> , 1987, "Murine T cell proliferation can be specifically augmented by macrophages fed with specific antigen: α_2 -Macroglobulin conjugate," <i>Biochem. Biophys. Res. Commun.</i> 146:26-31	
C149	OSADA <i>et al.</i> , 1988, "Antibodies against viral proteins can be produced effectively in response to the increased uptake of alpha 2-macroglobulin:viral protein conjugate by macrophages", <i>Biochem Biophys Res Commun.</i> 150(2):883-9	
C150	OTTO A. <i>et al.</i> , 1998, "Prostate-specific antigen forms complexes with human alpha 2-macroglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein." <i>J. Urol.</i> 159(1):297-303	
C151	PAL P.G., <i>et al.</i> , 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis." <i>Infect Immun.</i> 60(11):4781-92	
C152	PALLADINO <i>et al.</i> , 1987, "Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas", <i>Cancer Research</i> 47:5074-5079	
C153	PARDOLL, 2000, "Therapeutic vaccination for cancer", <i>Clin. Immunol.</i> 95(1 Pt 2): S44-62	
C154	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation," In: <i>Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Symposium</i> , Crispen, Ed. ITR, Chicago, IL, pp.189-204	
C155	PAUL, Ed., 1993 <i>Fundamental Immunology</i> , 3rd Edition, Raven Press, NY, p. 1158 and References 189-220 Cited On pp.1173-1174	
C156	PENG <i>et al.</i> , 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" <i>J. Immunol. Meth.</i> 204:13	
C157	PEREZ and WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", <i>J. Immunol.</i> <u>142</u> :3662-3667 (1989)	
C158	PINILLA-IBARZ <i>et al.</i> , 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," <i>Blood</i> 95(5):1781-1787	
C159	PREHN and MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas", <i>J. Natl. Cancer Inst.</i> <u>18</u> :769-778	
C160	QUI <i>et al.</i> , 1999, " α_2 macroglobulin enhances the clearance of endogenous soluble β -amyloid peptide via low density lipoprotein receptor-related protein in cortical neurons", <i>J. Neurochem.</i> 73(4):1393-1398	
C161	REPMANN <i>et al.</i> 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-Immunotherapy (ASI) Using Autologous Tumor Vaccine", <i>Anticancer Res.</i> 17:2879-2882	
C162	ROGERS <i>et al.</i> , 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-induced sarcomas, Meth A and CI-4," <i>Int. J. Cancer</i> 27:789-796	
C163	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", <i>Cell</i> 59:591-601	
C164	RÖTZSCHKE <i>et al.</i> , 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T cells", <i>Nature</i> 348:252-254	
C165	ROTZSCHKE, 1990, "Characterization of Naturally Occurring Minor Histocompatibility Peptides including H-4 and H-Y" <i>Science</i> 249: 283-287	
C166	SALK <i>et al.</i> , 1993, "A Strategy for Prophylactic Vaccination Against HIV", <i>Science</i> 260:1270-1272	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-298-999	APPLICATION NO. 10/784,012
	APPLICANT Srivastava, P.	
	FILING DATE February 20, 2004	ART UNIT 1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C167	SALLUSTO <i>et al.</i> , 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha," <i>J. Exp. Med.</i> 179(4):1109-1118	
C168	SANO <i>et al.</i> , 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity," <i>Cancer Immunol. Immunother.</i> 25(3):180-184	
C169	SAUTER <i>et al.</i> , 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", <i>J. Exp. Med.</i> 191:423-434	
C170	SCHREIBER, 1989 "Tumor Immunology", In: <i>Fundamental Immunology</i> , 2 nd Edition, Paul, ed., pp; 923-955	
C171	SCHUMACHER <i>et al.</i> , 1991, "Peptide Selection by MHC Class I Molecules", <i>Nature</i> 350:703-706	
C172	SILVA <i>et al.</i> , 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis", <i>Immunology</i> 82(2):244-8	
C173	SINGH-JASJUA <i>et al.</i> , 2000, "Cross Presentation of Glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis", <i>J. Exp. Med.</i> 191:1965-74	
C174	SOEIRO <i>et al.</i> , 2000, "Trypanosoma cruzi: Acute Infection Affects Expression of α -2-macroglobulin and A2MR/LRP Receptor Differently in C3H and C57BL/6 Mice", <i>Exper. Parasitology</i> 96: 97-107	
C175	SORGER and PELHAM, 1987, "The glucose-regulated protein grp94 is related to heat shock protein hsp90", <i>J. Mol. Biol.</i> 194(2):341-4	
C176	SPARKS <i>et al.</i> , 1976, "Immunology and adjuvant chemoimmunotherapy of breast cancer," <i>Arch. Surg.</i> 111:1057-1062	
C177	SRIVASTAVA and HEIKE, 1986, "Tumor-specific immunogenicity of stress-induced proteins: Convergence of two evolutionary pathways of antigen presentation?", <i>Seminars in Immunology</i> 3:57-64	
C178	SRIVASTAVA and OLD, 1989 "Gp96 Molecules: Recognition Elements in Tumor Immunity", <i>Human Tumor Antigens and Specific Tumor Therapy</i> , pages 63-71	
C179	SRIVASTAVA and UDONO, 1994, "Heat shock protein-peptide complexes in cancer immunotherapy" <i>Curr. Opin. Immunol.</i> 6:728	
C180	SRIVASTAVA <i>et al.</i> , 1990 "Immunization with Soluble Gp96 Antigens Elicits Tumor-Specific Cellular Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314	
C181	SRIVASTAVA <i>et al.</i> , 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma is also its Tumor-Associated Transplantation Antigen", <i>Int. J. Cancer</i> 33:417-422	
C182	SRIVASTAVA <i>et al.</i> , 1986, "Tumor rejection antigens of chemically induced sarcomas of inbred mice," <i>Proc. Natl. Acad. Sci. USA</i> 83(10):3407-3411	
C183	SRIVASTAVA <i>et al.</i> , 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors." <i>Proc. Natl. Acad. Sci USA</i> 84(11):3807-3811	
C184	SRIVASTAVA <i>et al.</i> , 1988, "Chromosomal assignment of the gene encoding the mouse tumor rejection antigen gp96," <i>Immunogenetics</i> 28:205-207	
C185	SRIVASTAVA <i>et al.</i> , 1988, "Individually distinct transplantation antigens of chemically induced mouse tumors," <i>Immunol. Today</i> 9:78-83	
C186	SRIVASTAVA <i>et al.</i> , 1989, "Identification of a Human Homologue of the Murine Tumor Rejection Antigen GP96," <i>Cancer Res.</i> 49:1341-1343	
C187	SRIVASTAVA <i>et al.</i> , 1991, "Protein Tumor Antigens", <i>Curr. Opin. Immunol.</i> 3:654-658	
C188	SRIVASTAVA <i>et al.</i> , 1991, "Stress-Induced Proteins in Immune Response to Cancer," <i>Curr. Top. Microbiol. Immunol.</i> 167:109-123	
C189	SRIVASTAVA <i>et al.</i> , 1993, "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock protein GP96: Implications for vaccination against cancer and infectious diseases", <i>J Cell Biochem Suppl</i> 17D:94 (Abstract NZ014)	
C190	SRIVASTAVA <i>et al.</i> , 1994, "Heat shock proteins transfer peptides during antigen processing and CTL priming", <i>Immunogenetics.</i> 39(2):93-8. Review	

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C191	SRIVASTAVA <i>et al.</i> , 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world", <i>Immunity</i> 8(6):657-65	
C192	SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm", <i>Experientia</i> . (11-12):1054-60	
C193	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation," <i>Adv. Cancer Res.</i> 62:153-177	
C194	STACK <i>et al.</i> , 1982, "Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer," <i>Thorax</i> 37(8):588-593	
C195	STEVENSON, 1999, "DNA vaccines against cancer: from genes to therapy," <i>Ann. Oncol.</i> 10:1413-8 Review	
C196	STRICKLAND <i>et al.</i> , 1990, "Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor", <i>J Biol Chem.</i> 265(29):17401-4	
C197	SUBBARAO <i>et al.</i> , 1992, "A General Overview of Viral Vaccine Development," <i>Genetically Engineered Vaccines</i> 327:51-57	
C198	SUTO <i>et al.</i> , 1995, "A Mechanism for the Specific Immunogenicity of Heat Shock Protein-Chaperoned Peptides," <i>Science</i> 269:1585-8	
C199	SUZUE <i>et al.</i> , 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway," <i>Proc. Natl. Acad. Sci. USA</i> 94(24):13146-51	
C200	SUZUE K., Young R.A., 1996, "Heat shock proteins as immunological carriers and vaccines. in: Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.), <i>Birkhauser/Springer</i> , 77: 451-465	
C201	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1" p24. <i>J Immunol.</i> 156(2):873-9	
C202	TAILOR <i>et al.</i> , 1990, "Nucleotide Sequence Of Human Prostatic Acid Phosphatase Determined From A Full-Length cDNA Clone", <i>Nucl. Acids Res.</i> 18:4928	
C203	TAMURA <i>et al.</i> , 1997, "Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations", <i>Science</i> 278(5335):117-20	
C204	THOMAS <i>et al.</i> , 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of Mammalian Tissue-Culture Cells", <i>Cold Springs Harbor Symp Quant Biol</i> 46:985-996	
C205	TODRYK <i>et al.</i> , 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake," <i>J. Immunol.</i> 163:1398-1408	
C206	UDONO and SRIVASTAVA, 1993, "Heat Shock Protein 70-associated Peptides Elicit Specific Cancer Immunity," <i>J. Exp. Med.</i> 178(4):1391-1396	
C207	UDONO <i>et al.</i> , 1994, "Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo", <i>Proc. Natl. Acad. Sci. USA</i> 91(8):3077-81	
C208	UDONO <i>et al.</i> , 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70," <i>J. Immunol.</i> , 152(11):5398-5403	
C209	UDONO, 1993, "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the tumors from which they are isolated", <i>J. Cell. Biochem. Suppl.</i> 17D:113 (Abstract NZ225)	
C210	ULLRICH <i>et al.</i> , 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," <i>Proc. Natl. Acad. Sci. USA</i> 83(10):3121-3125	
C211	VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors", <i>Cancer Res.</i> 28:2477-2483	
C212	VANBUSKIRK <i>et al.</i> , 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family", <i>J. Exp. Med.</i> 170:1799-1809	
C213	VIJAYASARADHI <i>et al.</i> , 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse <i>b</i> (Brown) Locus Gene Product", <i>J. Exp. Med.</i> 171:1375-1380	
C214	WALLNY <i>et al.</i> , 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". <i>Eur. J. Immunol</i> 22:655-659	
C215	WANG <i>et al.</i> , 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," <i>J. Immunol.</i> 166(1):490-497	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-298-999	10/784,012
	APPLICANT	
	Srivastava, P.	
	FILING DATE	ART UNIT
	February 20, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C216	WASSENBERG <i>et al.</i> , 1999, "Receptor mediated and fluid phase pathways for internalization of the ER Hsp90 chaperone GRP94 in murine macrophages," <i>J. Cell Science</i> 112: 2167-2175	
C217	WELCH <i>et al.</i> , 1982, "Purification of the Major Mammalian Heat Shock Proteins", <i>J. Biol. Chem.</i> 257:14949-14959	
C218	WELCH <i>et al.</i> , 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", <i>Mol. Cell. Biol.</i> 5:1229-1237	
C219	WELCH <i>et al.</i> , 1995, "Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment," <i>J. Cell. Biol.</i> 101:1198-1211	
C220	WELCH, 1993, "How Cells Respond to Stress," <i>Scientific American</i> 268(5):56-64	
C221	WU <i>et al.</i> , 1998, "Oxidized α_2 -Macroglobulin (α_2 M) Differentially Regulates Receptor Binding by Cytokines/Growth Factors: Implications for Tissue Injury and Repair Mechanisms in Inflammation", <i>J. Immunol.</i> 4356-4365	
C222	XIAO <i>et al.</i> 1995 Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment of human thyroglobulin. <i>Arch Biochem Biophys.</i> 1995 Jun 20;320(1):96-105	
C223	YAMAZAKI <i>et al.</i> , 1989, "Nucleotide sequence of a full-length cDNA for 90 kDa heat-shock protein from human peripheral blood lymphocytes", <i>Nucleic Acids Res.</i> 17(17):7108	
C224	YANG <i>et al.</i> , 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," <i>Int. J. Cancer</i> 83:532-540	
C225	YEDAVELLI <i>et al.</i> , 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" <i>Int. J. Mol. Med.</i> 3:243	
C226	YOUNG, 1990, "Stress proteins and immunology," <i>Annu. Rev. Immunol.</i> 8:401-420	
C227	YU <i>et al.</i> , 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", <i>Nature</i> 353:622-627	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	